These insights are crucial for developing targeted therapeutic strategies aimed at disrupting the PRMT5-driven pathways implicated in HCC progression, ultimately improving patient outcomes and treatment efficacy in combating this aggressive form of liver cancer. The gene discussed is PRMT5; the disease is hepatocellular carcinoma.